Novel Intraocular Melanoma Treatment options are getting better with the advent of laser surgery that removes the affected cells
Intraocular Melanoma is the most
common form of skin cancer that affects the iris of the eye. It is also one of
the most difficult to treat and may leave scars or no visible scar if proper
medical treatment is given. Treatment options are often limited due to its
advanced stage, however, it is still possible for this disease to be removed
surgically. It is important to seek medical treatment if any of these symptoms
are present. Melanoma is a type of skin cancer that generally occurs on the
iris of the eye, which is the colored part of the eyeball. This can cause
permanent damage to the iris and result in impaired vision.
This is the most common cause of
vision loss in humans. There are other less common causes of this condition,
however, it is not always possible to determine this in every case. Intraocular
melanoma is a difficult condition to treat. It is often resistant to the most
common forms of intraocular
melanoma treatment available. Doctors often resort to removing the mole or
getting it surgically removed in an attempt to cure the condition. However,
removal of the mole usually results in a scar being left behind. If the medical
treatment does not completely cure the condition, other forms of treatment
including laser surgery to remove the affected cells of the melanoma continue
to be performed.
Intraocular melanoma is the most
common cause of vision loss in humans. However, there are other less common
causes of vision loss. Some forms of skin cancer can cause temporary or
permanent vision loss. These include squamous cell lung cancer and melanoma.
Furthermore, some forms of cancer are linked to the development of vision loss.
For instance, if the melanoma that causes the vision problem is associated with
a primary tumor then the intraocular melanoma treatment for the primary tumor
is often used in conjunction with medical treatment to treat the melanoma.
Recently, in February 2019, Provecturs received the orphan drug designation
(ODD) from the U.S. Food and Drug Administration (FDA) for small molecule
oncolytic immunotherapy PV-10 for the treatment of ocular melanoma.
Comments
Post a Comment